{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:10:22Z","timestamp":1772575822871,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.leukres.2009.04.003","type":"journal-article","created":{"date-parts":[[2009,5,4]],"date-time":"2009-05-04T08:39:08Z","timestamp":1241426348000},"page":"184-189","source":"Crossref","is-referenced-by-count":24,"title":["2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Enrico","family":"Orciuolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Buda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Sordi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Barat\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Ciancia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2009.04.003_bib1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.critrevonc.2007.04.009","article-title":"Marginal-zone lymphoma","volume":"63","author":"Ferreri","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.leukres.2009.04.003_bib2","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"The non-Hodgkin's lymphoma classification project: a clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma","volume":"89","author":"Project","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.003_bib3","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/blood.V95.6.1950","article-title":"Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients","volume":"95","author":"Berger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.003_bib4","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","article-title":"Splenic marginal zone lymphoma: a prognostic model for clinical use","volume":"107","author":"Arcaini","year":"2006","journal-title":"Blood"},{"issue":"19 Suppl.","key":"10.1016\/j.leukres.2009.04.003_bib5","doi-asserted-by":"crossref","first-page":"iv70","DOI":"10.1093\/annonc\/mdn202","article-title":"Non-MALT marginal zone lymphomas","volume":"4","author":"Thieblemont","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.leukres.2009.04.003_bib6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11864-006-0014-9","article-title":"Management of marginal zone lymphomas","volume":"7","author":"Thieblemont","year":"2006","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.leukres.2009.04.003_bib7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3109\/10428199709050889","article-title":"Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma","volume":"26","author":"Pinotti","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2009.04.003_bib8","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1200\/JCO.1995.13.10.2524","article-title":"Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression","volume":"13","author":"Hammel","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2009.04.003_bib9","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1572-0241.2002.05460.x","article-title":"Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome","volume":"97","author":"Levy","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.leukres.2009.04.003_bib10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/sj.leu.2401710","article-title":"Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes","volume":"14","author":"Lefrere","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2009.04.003_bib11","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/cncr.20237","article-title":"Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma","volume":"100","author":"Zinzani","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2009.04.003_bib12","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1200\/JCO.2002.05.117","article-title":"Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study","volume":"20","author":"Jager","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2009.04.003_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/hon.717","article-title":"Low dose 2-CdA schedule activity in splenic marginal zone lymphomas","volume":"21","author":"Riccioni","year":"2003","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.leukres.2009.04.003_bib14","first-page":"ECR01","article-title":"Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma case report and review of the literature","volume":"89","author":"Jager","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2009.04.003_bib15","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.003_bib16","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2005.08.128","article-title":"Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy","volume":"23","author":"Martinelli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2009.04.003_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/hon.820","article-title":"Rituximab monotherapy is highly effective in splenic marginal zone lymphoma","volume":"25","author":"Kalpadakis","year":"2007","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.leukres.2009.04.003_bib18","doi-asserted-by":"crossref","first-page":"408a","DOI":"10.1182\/blood.V110.11.1358.1358","article-title":"A phase II study of fludarabine and rituximab for the treatment of marginal zone lymphomas","volume":"110","author":"Brown","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.003_bib19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0268-960X(96)90022-3","article-title":"2-chloro-2\u2019-deoxyadenosine: clinical applications in hematology","volume":"10","author":"Delannoy","year":"1996","journal-title":"Blood Rev"},{"key":"10.1016\/j.leukres.2009.04.003_bib20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1586\/14737140.8.4.535","article-title":"Cladribine in indolent non-Hodgkin's lymphoma","volume":"8","author":"Sigal","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.leukres.2009.04.003_bib21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.leu.2405068","article-title":"Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria","volume":"22","author":"Matutes","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2009.04.003_bib22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2009.04.003_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ajh.20492","article-title":"Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies","volume":"80","author":"Garcia-Suarez","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2009.04.003_bib24","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1200\/JCO.2005.05.018","article-title":"State-of-the-art therapeutics: marginal-zone lymphoma","volume":"23","author":"Bertoni","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2009.04.003_bib25","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1182\/blood-2002-07-2216","article-title":"Splenic marginal zone lymphoma","volume":"101","author":"Franco","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.003_bib26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/10428190009054887","article-title":"Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes","volume":"40","author":"Lefrere","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2009.04.003_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cncr.21931","article-title":"Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609001830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609001830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T22:04:10Z","timestamp":1589753050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212609001830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0145212609001830"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2009.04.003","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}